Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate

  • Novartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.
  • Novartis plans to manufacture the mRNA and bulk drug product of the CVnCoV vaccine candidate for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022. Delivery from manufacturing site in Kundl, Austria expected to start in summer 2021.
  • One of several agreements Novartis is reviewing on a global basis to help …
/by